Form 4: XBiotech Director Peter Libby Receives Stock Options

Director Peter Libby was granted stock options to purchase 37,500 shares of XBiotech Inc. common stock on June 20, 2024.

Summary

• Peter Libby, a director of XBiotech Inc., received nonstatutory stock options on June 20, 2024.
• The options allow Libby to purchase 37,500 shares of XBiotech's common stock at an exercise price of $5.12 per share.
• The options were granted under the company's 2015 Equity Incentive Plan.
• The options vest in two equal portions, with the first half vesting six months from the grant date (December 20, 2024) and the second half vesting one year from the grant date.
• The options expire ten years from the grant date (June 20, 2034).

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is generally neutral. It indicates that a director is incentivized to improve the company's performance, which is mildly positive.

Positives

• The granting of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes long-term commitment from the director.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director.
• Employees may see this as a standard compensation practice for executives.

Key Dates